Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease

To lighten the burden on health-care spending, switching from the infliximab originator to a biosimilar in patients with inflammatory bowel disease (IBD) is advocated. However, the uptake of biosimilars lacks initiatives aimed at educating patients.

Source: Digestive and Liver Disease - October 22, 2019 Category: Gastroenterology Authors: Vincent Haghnejad, Catherine Le Berre, Yoann Dominique, Camille Zallot, Francis Guillemin, Laurent Peyrin-Biroulet Tags: Alimentary Tract Source Type: research